FDA Okays Amgen's Prolia, But With Hefty Post-Marketing Requirements In Tow

Denosumab will be indicated for use in postmenopausal women with osteoporosis who are at high risk for fractures.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet